Exhaled markers of inflammatory lung diseases: ready for routine monitoring?
Exhaled markers of inflammatory lung diseases: ready for routine monitoring?
复制标题
DOI：
10.4414/smw.2004.10411
复制
发表时间：
2004-04
影响因子：
2.9
通讯作者：
S. Kharitonov
中科院分区：
文献类型：
--
作者：
S. Kharitonov
评估气道炎症对于研究包括哮喘和慢性阻塞性肺疾病（COPD）在内的许多肺部疾病的潜在机制非常重要。然而，由于监测炎症的困难，这些在常规临床实践中不能直接测量。气道炎症的存在和类型在临床上可能难以检测，并且可能导致开始适当治疗的延迟。非侵入性监测可以帮助肺部疾病的鉴别诊断，评估其严重程度和对治疗的反应。越来越多的证据表明，呼吸分析可能在哮喘、COPD、原发性纤毛运动障碍（PCD）和其他主要肺部疾病的诊断和临床管理中具有重要地位。本文综述了目前呼出气体的无创测量，如一氧化氮（NO），碳氢化合物，炎症标志物呼出气冷凝液（EBC）是否准备在临床实践中的常规使用。
Assessing airway inflammation is important for investigating the underlying mechanisms of many lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). Yet these are not measured directly in routine clinical practice because of the difficulties in monitoring inflammation. The presence and type of airway inflammation can be difficult to detect clinically, and may result in delays in initiating appropriate therapy. Non-invasive monitoring may assist in differential diagnosis of lung diseases, assessment of their severity and response to treatment. There is increasing evidence that breath analysis may have an important place in the diagnosis and clinical management of asthma, COPD, primary ciliary dyskinesia (PCD) and other major lung disease. The article reviews whether current noninvasive measurements of exhaled gases, such as nitric oxide (NO), hydrocarbons, inflammatory markers exhaled breath condensate (EBC) are ready for routine use in clinical practice.